The mucosal barrier has three major components, the mucus layer, the epithelial glycocalyx and the surface epithelium itself, whose integrity largely depends on tight junction function. In health, there is relatively little direct interaction between the luminal microbiota and the epithelium - the continuous mucus layer in the colon keeps the surface epithelium out of contact with bacteria and the ileo-caecal valve ensures that the distal small intestine is relatively microbe free. Most interaction takes place at the Peyer's patches in the distal ileum and their smaller colonic equivalents, the lymphoid follicles. Peyer's patches are overlain by a ‘dome' epithelium, 5% of whose cells are specialised M (microfold) epithelial cells, which act as the major portal of entry for bacteria. There are no goblet cells in the dome epithelium and M cells have a very sparse glycocalyx allowing easy microbial interaction. It is intriguing that the typical age range for the onset of Crohn's disease (CD) is similar to the age at which the number of Peyer's patches is greatest. Peyer's patches are commonly the sites of the initial lesions in CD and the ‘anti-pancreatic' antibody associated with CD has been shown to have as its epitope the glycoprotein 2 that is the receptor for type-1 bacterial fimbrial protein (fimH) on M cells. There are many reasons to believe that the mucosal barrier is critically important in the pathogenesis of inflammatory bowel disease (IBD). These include (i) associations between both CD and ulcerative colitis (UC) with genes that are relevant to the mucosal barrier; (ii) increased intestinal permeability in unaffected relatives of CD patients; (iii) increased immune reactivity against bacterial antigens, and (iv) animal models in which altered mucosal barrier, e.g. denudation of the mucus layer associated with oral dextran sulphate in rodents, induces colitis. Whilst some IBD patients may have genetic factors leading to weakening of the mucosal barrier, it is likely that environmental factors may be even more important. Some may be subtle and indirect, e.g. the effects of stress on the mucosa barrier, whilst others may be more obvious, e.g. the effect of pathogen-related gastroenteritis, known often to act as trigger for IBD relapse. We have also been very interested in the potentially harmful effects of ingested detergents - either by contamination of cutlery by inadequate rinsing or via ingestion of processed foods containing permitted emulsifiers. In vitro and ex vivo studies show that even very small trace amounts of these surfactants can greatly increase bacterial translocation. Implications for therapy are not yet so obvious. We advise our IBD patients to avoid processed foods containing emulsifiers and to rinse their dishes well - whilst accepting that there is no direct evidence yet to support this. Therapies that aim to enhance the mucosal barrier have yet to come to market, but trials of enteric-delivered phosphatidylcholine in UC are promising. The faecal concentration of mucus-degrading bacterial enzymes (particularly proteases, sulphatases and sialidases) correlates with disease activity in UC, and these represent good targets for therapy.

Keywords:
Bacterial translocation, Detergents, Emulsifiers, Glycocalyx, Intestinal permeability, Mucosal barrier, Tight junctions
1.
Johansson ME, Phillipson M, Petersson J, Velcich A, Holm L, Hansson GC: The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc Natl Acad Sci USA 2008;105:15064-15069.
2.
Johansson ME, Larsson JM, Hansson GC: The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 2011;108(suppl 1):4659-4665.
3.
Bäckström M, Ambort D, Thomsson E, Johansson ME, Hansson GC: Increased understanding of the biochemistry and biosynthesis of MUC2 and other gel-forming mucins through the recombinant expression of their protein domains. Mol Biotechnol 2013;54:250-256.
4.
Johansson ME, Ambort D, Pelaseyed T, Schütte A, Gustafsson JK, Ermund A, Subramani DB, Holmén-Larsson JM, Thomsson KA, Bergström JH, van der Post S, Rodriguez-Piñeiro AM, Sjövall H, Bäckström M, Hansson GC: Composition and functional role of the mucus layers in the intestine. Cell Mol Life Sci 2011;68:3635-3641.
5.
Frey A, Giannasca KT, Weltzin R, Giannasca PJ, Reggio H, Lencer WI, Neutra MR: Role of the glycocalyx in regulating access of microparticles to apical plasma membranes of intestinal epithelial cells: implications for microbial attachment and oral vaccine targeting. J Exp Med 1996;184:1045-1059.
6.
Barnich N, Darfeuille-Michaud A: Abnormal CEACAM6 expression in Crohn disease patients favors gut colonization and inflammation by adherent-invasive E. coli. Virulence 2010;1:281-282.
7.
McGuckin MA, Lindén SK, Sutton P, Florin TH: Mucin dynamics and enteric pathogens. Nat Rev Microbiol 2011;9:265-278.
8.
Moran AP, Gupta A, Joshi L: Sweet-talk: role of host glycosylation in bacterial pathogenesis of the gastrointestinal tract. Gut 2011;60:1412-1425.
9.
Yu QH, Yang Q: Diversity of tight junctions (TJs) between gastrointestinal epithelial cells and their function in maintaining the mucosal barrier. Cell Biol Int 2009;33:78-82.
10.
Hering NA, Fromm M, Schulzke J-D: Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 2012;590:1035-1044.
11.
Müller SL, Portwich M, Schmidt A, Utepbergenov DI, Huber O, Blasig IE, Krause G: The tight junction protein occludin and the adherens junction protein alpha-catenin share a common interaction mechanism with ZO-1. J Biol Chem 2005;280:3747-3756.
12.
Maiers JL, Peng X, Alan S, Fanning AS, DeMali KA: ZO-1 recruitment to α-catenin - a novel mechanism for coupling the assembly of tight junctions to adherens junctions. J Cell Sci Online 2013;126(pt 17):3904-3915
13.
Bevins CL, Martin-Porter E, Ganz T: Defensins and innate host defence of the gastrointestinal tract. Gut 1999;45:911-915.
14.
Zeiussig S, Burgel N, Gunzel D, Richter J, Mankertz J, Wahnschaffe U, Kroesen AJ, Zeitz M, Fromm M, Schulzke JD: Changes in expression and distribution of claudin 2.5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn's disease. Gut 2007;56:61-72.
15.
Hering NA, Fromm M, Schulzke J-D: Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics. J Physiol 2012;590:1035-1044.
16.
Arrieta MC, Madsen K, Doyle J, Meddings J: Reducing small intestinal permeability attenuates colitis in the IL10 gene-deficient mouse. Gut 2009;58:41-48.
17.
Kiesslich R, Duckworth CA, Moussata D, Gloeckner A, Lim LG, Goetz M, Pritchard DM, Galle PR, Neurath MF, Watson AJ: Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012;61:1146-1153.
18.
Podolsky DK, Isselbacher KJ: Composition of human colonic mucin. Selective alteration in inflammatory bowel disease. J Clin Invest 1983;72:142-153.
19.
Raouf AH, Parker N, Iddon D, Ryder S, Langdon-Brown B, Milton JD, Walker R, Rhodes JM: Ion exchange chromatography of purified colonic mucus glycoproteins in inflammatory bowel disease: absence of a selective subclass defect. Gut 1991;32:1139-1146.
20.
Rhodes JM, Campbell BJ, Yu LG: Lectin-epithelial interactions in the human colon. Biochem Soc Trans 2008;36:1482-1486.
21.
Campbell BJ, Rowe G, Leiper K, Rhodes JM: Increasing the intra-Golgi pH of cultured LS174T goblet-differentiated cells mimics the decreased mucin sulfation and increased Thomsen-Friedenreich antigen (Galβ1-3GalNAcα-) expression seen in colon cancer. Glycobiology 2001;11:385-393.
22.
Larsson JM, Karlsson H, Crespo JG, Johansson ME, Eklund L, Sjövall H, Hansson GC: Altered O-glycosylation profile of MUC2 mucin occurs in active ulcerative colitis and is associated with increased inflammation. Inflamm Bowel Dis 2011;17:2299-2307.
23.
Fu J, Wei B, Wen T, Johansson ME, Liu X, Bradford E, Thomsson KA, McGee S, Mansour L, Tong M, McDaniel JM, Sferra TJ, Turner JR, Chen H, Hansson GC, Braun J, Xia L: Loss of intestinal core 1-derived O-glycans causes spontaneous colitis in mice. J Clin Invest 2011;121:1657-1666.
24.
Bodger K, Halfvarson J, Dodson AR, Campbell F, Wilson S, Lee R, Lindberg E, Järnerot G, Tysk C, Rhodes JM: Altered colonic glycoprotein expression in unaffected monozygotic twins of inflammatory bowel disease patients. Gut 2006;55:973-977.
25.
Leiper K, Campbell BJ, Jenkinson MD, Milton JD, Yu L-G, Democratis J, Rhodes JM: Interaction between bacterial peptides, neutrophils and goblet cells: a possible mechanism for neutrophil recruitment and goblet cell depletion in colitis. Clin Sci (Lond) 2001;101:395-402.
26.
Shan M, Gentile M, Yeiser JR, Walland AC, Bornstein VU, Chen K, He B, Cassis L, Bigas A, Cols M, Comerma L, Huang B, Blander JM, Xiong H, Mayer L, Berin C, Augenlicht LH, Velcich A, Cerutti A: Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals. Science 2013;342:447-453
27.
Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, Büller HA, Dekker J, Van Seuningen I, Renes IB, Einerhand AW: Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 2006;131:117-129.
28.
Lu P, Burger-van Paassen N, van der Sluis M, Witte-Bouma J, Kerckaert JP, van Goudoever JB, Van Seuningen I, Renes IB: Colonic gene expression patterns of mucin Muc2 knockout mice reveal various phases in colitis development. Inflamm Bowel Dis 2011;17:2047-2057.
29.
Johansson ME, Gustafsson JK, Holmén-Larsson J, Jabbar KS, Xia L, Xu H, Ghishan FK, Carvalho FA, Gewirtz AT, Sjövall H, Hansson GC: Bacteria penetrate the normally impenetrable inner colon mucus layer in both murine colitis models and patients with ulcerative colitis. Gut 2014;63:281-291.
30.
Johansson ME, Gustafsson JK, Sjöberg KE, Petersson J, Holm L, Sjövall H, Hansson GC: Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One 2010;5:e12238.
31.
Rhee SH, Im E, Riegler M, Kokkotou E, O'brien M, Pothoulakis C: Pathophysiological role of Toll-like receptor 5 engagement by bacterial flagellin in colonic inflammation. Proc Natl Acad Sci USA 2005;102:13610-13615.
32.
Ryder SD, Raouf AH, Parker N, Walker RJ, Rhodes JM: Abnormal mucosal glycoprotein synthesis in inflammatory bowel diseases is not related to cigarette smoking. Digestion 1995;56:370-376.
33.
Rhodes JM, Black RR, Gallimore R, Savage A: Histochemical demonstration of desialylation and desulphation of normal and inflammatory bowel disease human rectal mucus by faecal extracts. Gut 1985;26:1312-1318.
34.
Tsai HH, Gibson G, Hart CA, Rhodes JM: A novel mucin sulphatase from human faeces: its identification, purification and characterization. Clin Sci (Lond) 1991;82:447-454.
35.
Tsai HH, Dwarakanath AD, Hart CA, Rhodes JM: Increased faecal mucin sulphatase activity in ulcerative colitis: a potential target for treatment. Gut 1995;36:570-576.
36.
Singh R, Campbell BJ, Yu L-G, Fernig DG, Milton JD, Goodlad RA, FitzGerald AJ, Rhodes JM: Cell surface-expressed Thomsen-Friedenreich antigen in colon cancer is predominantly carried on high molecular weight splice variants of CD44. Glycobiology 2001;11:587-592.
37.
Ryder SD, Jacyna MR, Levi AJ, Rizzi PM, Rhodes JM: Eating peanuts increases rectal proliferation in individuals with mucosal expression of peanut lectin receptor. Gastroenterology 1998;114:44-49.
38.
Martin HM, Campbell BJ, Hart CA, Mpofu C, Nayar M, Singh R, Englyst H, Williams HF, Rhodes JM: Enhanced Escherichia coli adherence and invasion in Crohn's disease and colon cancer. Gastroenterology 2004;127:80-93.
39.
Prorok-Hamon M, Friswell MK, Alswied A, Roberts CL, Song F, Flanagan PK, Knight P, Codling C, Marchesi JR, Winstanley C, Hall N, Rhodes JM, Campbell BJ: Colonic mucosa-associated diffusely adherent afaC+ Escherichia coli expressing lpfA and pks are increased in inflammatory bowel disease and colon cancer. Gut 2013, Epub ahead of print.
40.
Barnich N, Carvalho FA, Glasser AL, Darcha C, Jantscheff P, Allez M, Peeters H, Bommelaer G, Desreumaux P, Colombel JF, Darfeuille-Michaud A: CEACAM6 acts as a receptor for adherent-invasive E. coli, supporting ileal mucosa colonization in Crohn disease. J Clin Invest 2007;117:1566-1574.
41.
Ryan P, Kelly RG, Lee G, Collins JK, O'Sullivan GC, O'Connell J, Shanahan F: Bacterial DNA within granulomas of patients with Crohn's disease - detection by laser capture microdissection and PCR. Am J Gastroenterol 2004;99:1539-1543.
42.
Swidsinski A, Ladhoff A, Pernthaler A, Swidsinski S, Loening-Baucke V, Ortner M, Weber J, Hoffmann U, Schreiber S, Dietel M, Lochs H: Mucosal flora in inflammatory bowel disease. Gastroenterology 2002;122:44-54.
43.
Sansonetti PJ, Phalipon A: M cells as ports of entry for enteroinvasive pathogens: mechanisms of interaction, consequences for the disease process. Semin Immunol 1999;11:193-203.
44.
Chassaing B, Rolhion N, de Vallée A, Salim SY, Prorok-Hamon M, Neut C, Campbell BJ, Söderholm JD, Hugot JP, Colombel JF, Darfeuille-Michaud A: Crohn disease-associated adherent-invasive E. coli bacteria target mouse and human Peyer's patches via long polar fimbriae. J Clin Invest 2011;121:966-975.
45.
Van Kruiningen HJ, Ganley LM, Freda BJ: The role of Peyer's patches in the age-related incidence of Crohn's disease. J Clin Gastroenterol 1997;25:470-475.
46.
Van Kruiningen HJ, West AB, Freda BJ, Holmes KA: Distribution of Peyer's patches in the distal ileum. Inflamm Bowel Dis 2002;8:180-185.
47.
Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, Porstmann T, Laass MW, Henker J, Büning C, Feist E, Conrad K: Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. Gut 2009;58:1620-1628.
48.
Hase K, Kawano K, Nochi T, Pontes GS, Fukuda S, Ebisawa M, Kadokura K, Tobe T, Fujimura Y, Kawano S, Yabashi A, Waguri S, Nakato G, Kimura S, Murakami T, Iimura M, Hamura K, Fukuoka S, Lowe AW, Itoh K, Kiyono H, Ohno H: Uptake through glycoprotein 2 of FimH(+) bacteria by M cells initiates mucosal immune response. Nature 2009;462:226-230.
49.
Fujimura Y, Kamoi R, Iida M: Pathogenesis of aphthoid ulcers in Crohn's disease: correlative findings by magnifying colonoscopy, electron microscopy, and immunohistochemistry. Gut 1996;38:724-732.
50.
Krauss E, Agaimy A, Neumann H, Schulz U, Kessler H, Hartmann A, Neurath MF, Raithel M, Mudter J: Characterization of lymphoid follicles with red ring signs as first manifestation of early Crohn's disease by conventional histopathology and confocal laser endomicroscopy. Int J Clin Exp Pathol 2012;5:411-421.
51.
Subramanian S, Rhodes JM, Hart CA, Tam B, Roberts CL, Smith SL, Corkill JE, Winstanley C, Virji M, Campbell BJ: Characterization of epithelial IL-8 response to inflammatory bowel disease mucosal E. coli and its inhibition by mesalamine. Inflamm Bowel Dis 2008;14:162-175.
52.
Finnie IA, Campbell BJ, Taylor BA, Milton JD, Sadek SK, Yu LG, Rhodes JM: Stimulation of colonic mucin synthesis by corticosteroids and nicotine. Clin Sci (Lond) 1996;91:359-364.
53.
Treede I, Braun A, Sparla R, Kühnel M, Giese T, Turner JR, Anes E, Kulaksiz H, Füllekrug J, Stremmel W, Griffiths G, Ehehalt R: Anti-inflammatory effects of phosphatidylcholine. J Biol Chem 2007;282:27155-27164.
54.
Stremmel W, Ehehalt R, Autschbach F, Karner M: Phosphatidylcholine for steroid-refractory chronic ulcerative colitis: a randomized trial. Ann Intern Med 2007;147:603-610.
55.
Roberts CL, Keita AV, Duncan SH, O'Kennedy N, Söderholm JD, Rhodes JM, Campbell BJ: Translocation of Crohn's disease E. coli across M-cells: contrasting effects of soluble plant fibres and emulsifiers. Gut 2010;59:1331-1339.
56.
Roberts CL, Keita AV, Parsons BN, Prorok-Hamon M, Knight P, Winstanley C, O'Kennedy N, Söderholm JD, Rhodes JM, Campbell BJ: Soluble plantain fibre blocks adhesion and M-cell translocation of intestinal pathogens. J Nutr Biochem 2013;24:97-103.
57.
Flanagan P, Campbell BJ, Rhodes JM: Bacteria in the pathogenesis of inflammatory bowel disease. Biochem Soc Trans 2011;39:1067-1072.
58.
Dwarakanath AD, Campbell BJ, Tsai HH, Sunderland D, Hart CA, Rhodes JM: Faecal mucinase activity in inflammatory bowel disease. Gut 1995;37:58-62.
59.
Ryder SD, Walker RJ, Jones H, Rhodes JM: Rectal bismuth subsalicylate as therapy for ulcerative colitis. Aliment Pharmacol Therap 1990;4:333-338.
60.
Gullikson GW, Cline WS, Lorenzsonn V, Benz L, Olsen WA, Bass P: Effects of anionic surfactants on hamster small intestinal membrane structure and function: relationship to surface activity. Gastroenterology 1977;73:501-511.
61.
Aungst BJ: Intestinal permeation enhancers. J Pharm Sci 2000;89:429-442.
62.
Mercurius-Taylor LA, Jayaraj AP, Clark CG: Is chronic detergent ingestion harmful to the gut? Br J Ind Med 1984;41:279-281.
63.
Münch A, Söderholm JD, Ost A, Carlsson AH, Magnusson KE, Ström M: Low levels of bile acids increase bacterial uptake in colonic biopsies from patients with collagenous colitis in remission. Aliment Pharmacol Ther 2011;33:954-960.
64.
Münch A, Ström M, Söderholm JD: Dihydroxy bile acids increase mucosal permeability and bacterial uptake in human colon biopsies. Scand J Gastroenterol 2007;42:1167-1174.
65.
Roberts CL, Rushworth SL, Richman E, Rhodes JM: Hypothesis: increased consumption of emulsifiers as an explanation for the rising incidence of Crohn's disease. J Crohns Colitis 2013;7:338-341.
66.
Richman E, Rhodes JM: Review article: evidence-based dietary advice for patients with inflammatory bowel disease. Aliment Pharmacol Ther 2013;38:1156-1171.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.